Does ruxolitinib really prolong survival in individuals with myelofibrosis? The never-ending story.
作者信息
Barosi Giovanni, Gale Robert Peter
机构信息
General Medicine 2, Center for the Study of Myelofibrosis, Policlinico S. Matteo Foundation, Istituto di Ricovero e Cura a Carattere Scientifico, Pavia, Italy; and.
Centre for Haematology Research, Department of Immunology and Inflammation, Imperial College London, London, United Kingdom.
出版信息
Blood Adv. 2022 Apr 12;6(7):2331-2333. doi: 10.1182/bloodadvances.2022007230.
Abstract
摘要
相似文献
1
Does ruxolitinib really prolong survival in individuals with myelofibrosis? The never-ending story.芦可替尼真的能延长骨髓纤维化患者的生存期吗？这是个没完没了的故事。
Blood Adv. 2022 Apr 12;6(7):2331-2333. doi: 10.1182/bloodadvances.2022007230.
2
Impact of ruxolitinib on survival of patients with myelofibrosis in the real world: update of the ERNEST Study.芦可替尼对真实世界中骨髓纤维化患者生存的影响：ERNEST研究更新
Blood Adv. 2022 Jan 25;6(2):373-375. doi: 10.1182/bloodadvances.2021006006.
3
A neutrophilic dermatosis following treatment of myelofibrosis with ruxolitinib: An emerging phenomenon?芦可替尼治疗骨髓纤维化后出现的嗜中性皮肤病：一种新出现的现象？
Australas J Dermatol. 2021 Nov;62(4):e607-e609. doi: 10.1111/ajd.13717. Epub 2021 Sep 16.
4
RR6 prognostic model provides information about survival for myelofibrosis treated with ruxolitinib: validation in a real-life cohort.RR6预后模型提供了关于芦可替尼治疗骨髓纤维化患者生存情况的信息：在真实队列中的验证
Blood Adv. 2022 Aug 9;6(15):4424-4426. doi: 10.1182/bloodadvances.2022008158.
5
Hepcidin is elevated in primary and secondary myelofibrosis and remains elevated in patients treated with ruxolitinib.在原发性和继发性骨髓纤维化中，铁调素水平升高，并且在用鲁索替尼治疗的患者中仍保持升高。
Br J Haematol. 2022 May;197(4):e49-e52. doi: 10.1111/bjh.18044. Epub 2022 Feb 6.
6
Limited activity of fedratinib in myelofibrosis patients relapsed/refractory to ruxolitinib 20 mg twice daily or higher: A real-world experience.费拉替尼对每日两次服用20毫克或更高剂量芦可替尼后复发/难治的骨髓纤维化患者疗效有限：一项真实世界经验。
Br J Haematol. 2022 Aug;198(4):e54-e58. doi: 10.1111/bjh.18284. Epub 2022 May 25.
7
Updated recommendations on the use of ruxolitinib for the treatment of myelofibrosis.更新的芦可替尼治疗骨髓纤维化的使用建议。
Hematology. 2022 Dec;27(1):23-31. doi: 10.1080/16078454.2021.2009645.
8
Effects of ruxolitinib on secondary myelofibrosis following chronic neutrophilic leukemia with the CSF3R T618I mutation.鲁索替尼对伴有CSF3R T618I突变的慢性嗜中性粒细胞白血病继发骨髓纤维化的影响。
Ann Hematol. 2021 Oct;100(10):2639-2641. doi: 10.1007/s00277-020-04185-1. Epub 2020 Jul 16.
9
Ruxolitinib with Navitoclax Is Efficacious and Safe in Myelofibrosis.芦可替尼联合纳维托昔单抗治疗骨髓纤维化疗效确切且安全。
Cancer Discov. 2022 May 2;12(5):OF4. doi: 10.1158/2159-8290.CD-RW2022-037.
10
Efficacy and safety of ruxolitinib in patients with myelofibrosis: a retrospective and multicenter experience in Turkey.芦可替尼治疗骨髓纤维化患者的疗效和安全性：土耳其的回顾性多中心经验。
Turk J Med Sci. 2021 Jun 28;51(3):1033-1042. doi: 10.3906/sag-1812-70.
引用本文的文献
1
JAK2 inhibition mediates clonal selection of RAS pathway mutations in myeloproliferative neoplasms.JAK2抑制介导骨髓增殖性肿瘤中RAS通路突变的克隆选择。
Nat Commun. 2025 Jul 8;16(1):6270. doi: 10.1038/s41467-025-60884-1.
2
Outcomes for ruxolitinib only versus combination with interferon in treating patients with myelofibrosis.仅使用鲁索替尼与联合使用干扰素治疗骨髓纤维化患者的疗效比较。
Blood Neoplasia. 2025 Mar 3;2(2):100082. doi: 10.1016/j.bneo.2025.100082. eCollection 2025 May.
3
When, which and how to switch: Navigating JAK inhibitors in myelofibrosis.何时、何种情况以及如何换药：骨髓纤维化中JAK抑制剂的应用指南
Br J Haematol. 2024 Nov 27. doi: 10.1111/bjh.19929.
4
The Gordian knot: ruxolitinib or transplants for high-risk myelofibrosis.戈尔迪之结：芦可替尼还是用于高危骨髓纤维化的移植治疗
Haematologica. 2024 Nov 1;109(11):3469-3470. doi: 10.3324/haematol.2024.285972.
5
Molecular Genetic Profile of Myelofibrosis: Implications in the Diagnosis, Prognosis, and Treatment Advancements.骨髓纤维化的分子遗传学特征：对诊断、预后及治疗进展的意义
Cancers (Basel). 2024 Jan 25;16(3):514. doi: 10.3390/cancers16030514.
6
Upfront allogeneic transplantation versus JAK inhibitor therapy for patients with myelofibrosis: a North American collaborative study. upfront 同种异体移植与 JAK 抑制剂治疗骨髓纤维化患者：一项北美合作研究。
Bone Marrow Transplant. 2024 Feb;59(2):196-202. doi: 10.1038/s41409-023-02146-6. Epub 2023 Nov 8.
7
Blast phase myeloproliferative neoplasm: contemporary review and 2024 treatment algorithm.急变期骨髓增殖性肿瘤：当代综述与 2024 年治疗算法。
Blood Cancer J. 2023 Jul 18;13(1):108. doi: 10.1038/s41408-023-00878-8.
8
SOHO State of the Art Updates and Next Questions: Novel Therapeutic Strategies in Development for Myelofibrosis.SOHO 最新进展及未来展望：骨髓纤维化治疗策略的新进展。
Clin Lymphoma Myeloma Leuk. 2023 Apr;23(4):219-231. doi: 10.1016/j.clml.2022.12.014. Epub 2023 Jan 6.
本文引用的文献
1
Risk of mortality and second malignancies in primary myelofibrosis before and after ruxolitinib approval.芦可替尼获批前后原发性骨髓纤维化的死亡率及第二原发性恶性肿瘤风险
Leuk Res. 2022 Jan;112:106770. doi: 10.1016/j.leukres.2021.106770. Epub 2021 Dec 9.
2
Impact of ruxolitinib on survival of patients with myelofibrosis in the real world: update of the ERNEST Study.芦可替尼对真实世界中骨髓纤维化患者生存的影响：ERNEST研究更新
Blood Adv. 2022 Jan 25;6(2):373-375. doi: 10.1182/bloodadvances.2021006006.
3
Evolution of the Randomized Clinical Trial in the Era of Precision Oncology.精准肿瘤学时代的随机临床试验演变。
JAMA Oncol. 2021 May 1;7(5):728-734. doi: 10.1001/jamaoncol.2021.0379.
4
Momelotinib therapy for myelofibrosis: a 7-year follow-up.莫雷洛替尼治疗骨髓纤维化：7 年随访结果。
Blood Cancer J. 2018 Mar 7;8(3):29. doi: 10.1038/s41408-018-0067-6.
5
Does ruxolitinib prolong the survival of patients with myelofibrosis?芦可替尼能否延长骨髓纤维化患者的生存期？
Blood. 2017 Feb 16;129(7):832-837. doi: 10.1182/blood-2016-11-731604. Epub 2016 Dec 28.
6
Critical appraisal of the role of ruxolitinib in myeloproliferative neoplasm-associated myelofibrosis.鲁索替尼在骨髓增殖性肿瘤相关骨髓纤维化中作用的批判性评价
Onco Targets Ther. 2015 May 18;8:1091-102. doi: 10.2147/OTT.S31916. eCollection 2015.
7
Janus kinase-1 and Janus kinase-2 inhibitors for treating myelofibrosis.用于治疗骨髓纤维化的Janus激酶1和Janus激酶2抑制剂。
Cochrane Database Syst Rev. 2015 Apr 10;2015(4):CD010298. doi: 10.1002/14651858.CD010298.pub2.
8
Does ruxolitinib improve survival of persons with MPN-associated myelofibrosis? Should it?鲁索替尼能否提高骨髓增殖性肿瘤相关骨髓纤维化患者的生存率？应该这样做吗？
Leukemia. 2014 Nov;28(11):2267-70. doi: 10.1038/leu.2014.220. Epub 2014 Jul 16.
9
Impact of ruxolitinib on the natural history of primary myelofibrosis: a comparison of the DIPSS and the COMFORT-2 cohorts.芦可替尼对原发性骨髓纤维化自然病程的影响：DIPSS 和 COMFORT-2 队列的比较。
Blood. 2014 Mar 20;123(12):1833-5. doi: 10.1182/blood-2013-12-544411. Epub 2014 Jan 17.
10
Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis.COMFORT-II 研究的 3 年疗效、安全性和生存结果，该研究是一项比较芦可替尼与骨髓纤维化最佳可用疗法的 3 期研究。
Blood. 2013 Dec 12;122(25):4047-53. doi: 10.1182/blood-2013-02-485888. Epub 2013 Oct 30.
Zotero 插件